Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates
Open Access
- 1 January 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (1) , 400-404
- https://doi.org/10.1128/aac.47.1.400-404.2003
Abstract
The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90% of the isolates tested were inhibited [MIC 90 s], ≤1 μg/ml). In addition, it was also very potent against most members of the Enterobacteriaceae , with most MIC 90 s being ≤2 μg/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomonas maltophilia are included in the in vitro spectrum of tigecycline activity.Keywords
This publication has 16 references indexed in Scilit:
- Susceptibilities of Mycoplasma hominis, M. pneumoniae , and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and QuinolonesAntimicrobial Agents and Chemotherapy, 2001
- GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteriaInternational Journal of Antimicrobial Agents, 2001
- Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolatesJournal of Antimicrobial Chemotherapy, 2001
- Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental EndocarditisAntimicrobial Agents and Chemotherapy, 2000
- In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 2000
- Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound PathogensAntimicrobial Agents and Chemotherapy, 2000
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2000
- In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2000
- Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936Bioorganic & Medicinal Chemistry Letters, 1999